HomeCompareRLFTD vs EPRT

RLFTD vs EPRT: Dividend Comparison 2026

RLFTD yields 49.02% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RLFTD wins by $311.1K in total portfolio value
10 years
RLFTD
RLFTD
● Live price
49.02%
Share price
$4.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$374.5K
Annual income
$74,708.98
Full RLFTD calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RLFTD vs EPRT

📍 RLFTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLFTDEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLFTD + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLFTD pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD
Annual income on $10K today (after 15% tax)
$4,166.67/yr
After 10yr DRIP, annual income (after tax)
$63,502.63/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, RLFTD beats the other by $52,588.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + EPRT for your $10,000?

RLFTD: 50%EPRT: 50%
100% EPRT50/50100% RLFTD
Portfolio after 10yr
$218.9K
Annual income
$43,774.85/yr
Blended yield
19.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RLFTD
No analyst data
Altman Z
-12.4
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys
0
EPRT buys
0
No recent congressional trades found for RLFTD or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLFTDEPRT
Forward yield49.02%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$374.5K$63.4K
Annual income after 10y$74,708.98$12,840.73
Total dividends collected$297.4K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RLFTD vs EPRT ($10,000, DRIP)

YearRLFTD PortfolioRLFTD Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,602$4,901.96$11,205$505.18+$4.4KRLFTD
2$23,842$7,147.68$12,672$682.46+$11.2KRLFTD
3$35,719$10,208.01$14,490$930.48+$21.2KRLFTD
4$52,512$14,292.70$16,786$1,282.69+$35.7KRLFTD
5$75,825$19,637.72$19,753$1,791.56+$56.1KRLFTD
6$107,634$26,501.16$23,677$2,541.64+$84.0KRLFTD
7$150,326$35,157.45$29,008$3,672.99+$121.3KRLFTD
8$206,739$45,889.95$36,463$5,425.08+$170.3KRLFTD
9$280,193$58,982.29$47,238$8,221.57+$233.0KRLFTD
10$374,515$74,708.98$63,385$12,840.73+$311.1KRLFTD

RLFTD vs EPRT: Complete Analysis 2026

RLFTDStock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RLFTD vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHDRLFTD vs JEPIRLFTD vs ORLFTD vs KORLFTD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.